Abscisic acid compound targeting PPAR-gamma for diabetes
This patent covers the use of abscisic acid (ABA) — a naturally occurring plant hormone also found in mammals — as a therapeutic agent for metabolic and inflammatory diseases. ABA works by activating a protein called PPAR-gamma, which plays a central role in regulating insulin sensitivity, fat storage, and immune cell behavior. By modulating this pathway, ABA can reduce the infiltration of inflammatory immune cells into fat and muscle tissue, a key driver of type 2 diabetes and obesity-related inflammation. The invention covers administering ABA in various forms, alone or in combination with other treatments, to address conditions ranging from type 2 diabetes and prediabetes to inflammatory bowel disease, multiple sclerosis, and arthritis.
What you could build
A nutraceutical supplement or pharmaceutical compound containing ABA targeting patients with type 2 diabetes, prediabetes, or obesity-related inflammation; buyers would include specialty pharma companies, functional food and supplement brands, and potentially biotech licensees pursuing PPAR-gamma-pathway drugs.
Who in Virginia should care
Virginia-based pharmaceutical and biotech firms, as well as dietary supplement companies in the mid-Atlantic corridor, would be plausible licensees or development partners.
Readiness: Lab validated
Concept — described but not yet demonstrated. Lab validated — supported by experimental results in the patent. Prototype likely — the text describes a built, working embodiment.
Readiness is inferred from the patent text, not from a lab visit.
The record
- Inventors
- Josep BASSAGANYA-RIERA, Amir GURI, Raquel HONTECILLAS
- Granted
- June 22, 2010
- Status
- Granted patent
- Patent number
- 7741367
Ready to talk?
Virginia Tech Intellectual Properties handles licensing for this technology.
Prosim summaries are generated from public patent text and are not legal advice.